Dual anti‐HER2 therapy had a better median PFS time than pyrotinib alone for patients with visceral metastasis (9.7 vs. 8.2 months, p = 0.033, Figure 2A) and bone metastasis (10.2 vs. 8.3 months, p = 0.049, Figure 2B), while not for patients with local metastasis (9.7 vs. 8.4 months, p = 0.280, Figure 2C) and brain metastasis (7.6 vs. 6.5 months, p = 0.152, Figure 2D). Here, ERBB2 is linked to bone metastasis.